It's a Christmas miracle to expect any progress. 12/28/2025
The user shared their hair regrowth progress using finasteride, minoxidil, microneedling, and tretinoin cream, noting inconsistency in their routine. They plan to be more consistent with treatments in the future.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity What else is good. Besides the big 3.
Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.
community 11 months on fin + min. Thoughts?
A user shared progress pictures after 11 months on finasteride and minoxidil, with intermittent microneedling. The community responded positively, noting significant hair regrowth and encouraging continued treatment.
community 2.5 Years Fin/Min - progress pics
The user achieved significant hair regrowth using topical Minoxidil and Finasteride over 2.5 years, with results plateauing after a year. They experienced minimal side effects and used microneedling to enhance results.
community Can dut save my temples? I've been on fin for 2 years but im plateauing
OP is considering adding dutasteride to their regimen of finasteride and minoxidil to address hair loss plateauing. Users suggest oral minoxidil, microneedling, and possibly a hair transplant, with mixed opinions on dutasteride's effectiveness for temple regrowth.
community 25 years on Finasteride and it's not working anymore.
A 47-year-old has been using finasteride for 25 years for hair loss, but it's less effective now. Suggestions include switching to dutasteride, stopping anastrozole, and trying minoxidil, microneedling, and possibly TRT.
community Please, if you are thinking about starting meds, do it as early as possible
Start hair loss treatments early for best results. Finasteride, Dutasteride, Minoxidil, and microneedling are commonly used, with some users experiencing side effects but often regretting delayed treatment.
Related Research
6 / 6 results
research Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review
This review discusses the potential of using SULT1A1 expression in the scalp as a biomarker to predict response to minoxidil treatment for androgenetic alopecia, but reports no new clinical results.
research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.
research Cosmetic Approach for Men
This chapter reviews differences in dermatological treatments and conditions between male and female patients, particularly noting the impacts of sex steroids on various skin processes, but presents no new clinical findings.
research Clinical Trials and Hair Loss
This review explores the current treatments for different types of alopecia, emphasizing the need for well-designed clinical trials and highlighting that most therapies are used off-label, as only androgenetic alopecia has FDA-approved drugs.
research A review of the treatment of male pattern hair loss
This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.
research Topical Treatment for Scarring and Non-Scarring Alopecia: An Overview of the Current Evidence
This review discusses the progress in research on topical formulations for treating alopecia, highlighting potential advantages of advanced formulation technologies but reporting no new clinical results.